Soligenix Inc. Market Cap ($7.75 Million)
Market Cap & Net Worth: Soligenix Inc. (SNGX)
Soligenix Inc. market cap. Soligenix Inc. (NASDAQ:SNGX) has a market capitalization of $7.75 Million ($7.75 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27557 globally and #5708 in its home market, demonstrating a 1.71% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Soligenix Inc.'s stock price $0.36 by its total outstanding shares 21765479 (21.77 Million). Also see cash flow conversion of Soligenix Inc. for how efficiently the company converts equity into cash flow.
Soligenix Inc. Market Cap History (2015–2026)
Soligenix Inc. market cap history from 2015 to 2026. Data shows change from $59.03 Billion to $7.75 Million (-55.47% CAGR). Check SNGX live share price for real-time trading data and today's change.
Index Memberships
Soligenix Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #780 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2523 of 3165 |
Weight: Soligenix Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Soligenix Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Soligenix Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SNGX shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
491.39x
Soligenix Inc.'s market cap is 491.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $11.75 Billion | $10.45 Million | -$3.25 Million | 1124.83x | N/A |
| 2017 | $11.59 Billion | $5.43 Million | -$7.15 Million | 2134.40x | N/A |
| 2018 | $4.49 Billion | $5.24 Million | -$8.90 Million | 857.16x | N/A |
| 2019 | $7.57 Billion | $3.22 Million | -$9.36 Million | 2355.48x | N/A |
| 2020 | $6.69 Billion | $1.93 Million | -$17.69 Million | 3463.48x | N/A |
| 2021 | $3.45 Billion | $33.35K | -$12.55 Million | 103421.76x | N/A |
| 2022 | $2.36 Billion | $250.00K | -$13.80 Million | 9444.48x | N/A |
| 2023 | $263.69 Million | $839.36K | -$6.14 Million | 314.16x | N/A |
| 2024 | $58.66 Million | $119.37K | -$8.27 Million | 491.39x | N/A |
Competitor Companies of SNGX by Market Capitalization
Companies near Soligenix Inc. in the global market cap rankings as of November 4, 2026. Also see Soligenix Inc. (SNGX) total assets for a full breakdown of the balance sheet.
Key companies related to Soligenix Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Soligenix Inc. (2015–2026)
Market capitalization of Soligenix Inc. from 2015 to today. Between 2015 and today, Soligenix Inc.'s market cap moved from $59.03 Billion to $ 7.75 Million, with a yearly change of -55.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.75 Million | -73.43% |
| 2025 | $29.17 Million | -50.28% |
| 2024 | $58.66 Million | -77.76% |
| 2023 | $263.69 Million | -88.83% |
| 2022 | $2.36 Billion | -31.55% |
| 2021 | $3.45 Billion | -48.41% |
| 2020 | $6.69 Billion | -11.72% |
| 2019 | $7.57 Billion | +68.60% |
| 2018 | $4.49 Billion | -61.25% |
| 2017 | $11.59 Billion | -1.36% |
| 2016 | $11.75 Billion | -80.09% |
| 2015 | $59.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Soligenix Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.75 Million USD |
| MoneyControl | $7.75 Million USD |
| MarketWatch | $7.75 Million USD |
| marketcap.company | $7.75 Million USD |
| Reuters | $7.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial fo… Read more